Skip to main content

Table 4 Outcomes at 30 days

From: Balloon-expandable transcatheter aortic valve implantation with or without pre-dilation – results of a meta-analysis of 3 multicenter registries

 

TAVI with BAV

TAVI without BAV

OR (95% CI)

N

%

N

%

Not-adjusted

Adjusteda

Death (%)

327

1.8

343

1.5

0.79 (0.23–2.65)

0.4 (0.06–1.86)

Stroke (%)

327

0.9

341

0.3

0.32 (0.02–2.5)

0.79 (0.02–27.7)

Non-fatal MI (%)

336

0.6

349

0.9

1.45 (0.24–11.05)

1.29 (0.12–13.1)

New-onset dialysis (%)

332

3.9

348

3.7

0.95 (0.43–2.1)

0.97 (0.4–2.32)

Creatinine increase (%)

268

1.5

210

1.4

0.96 (0.19–4.38)

0.42 (0.02–3.22)

Permanent pacemaker implantation (%)

337

10.1

350

8.6

0.84 (0.5–1.4)

1.17 (0.62–2.2)

Life-threatening bleeding (%)

333

3.0

345

1.4

0.48 (0.15–1.35)

0.42 (0.09–1.48)

Major vascular complications (%)

333

4.5

345

3.5

0.76 (0.35–1.66)

0.63 (0.21–1.65)

Hospitalization (%)

333

2.7

344

1.2

0.42 (0.11–1.31)

0.48 (0.09–1.9)

Valve dysfunction (%)

322

0.9

337

0.0

NYHA Class III or IV (%)

336

54.5

346

17.6

0.18 (0.13–0.25)

0.18 (0.12–0.27)

CCS grading of angina pectoris Class III or IV (%)

308

1.6

296

1.0

0.62 (0.13–2.55)

0.98 (0.18–4.8)

  1. BAV Balloon aortic valvuloplasty, CI Confidence interval, CCS Canadian cardiovascular society, MI Myocardial infarction, NYHA New York Heart Association, OR Odds ratio, TAVI Transcatheter aortic valve implantation
  2. adata were adjusted for age, gender, prior MI, stroke / TIA, creatinine, ejection fraction and NYHA class